|Assessment Status||Assessment process complete|
|Indication||For the treatment of moderate to severe rheumatoid arthritis.|
|Rapid review commissioned||20/11/2009|
|Rapid review completed||11/05/2010|
|Rapid review outcome||Reimbursement recommended following price review, June 2010.|
The review group did not consider golimumab cost-effective at the submitted price in May 2010.
Following a price reduction the review group now consider golimumab to be cost-effective. June 2010.